Navigation Links
Rigel To Focus On ITP, DLE And Dry Eye
Date:9/5/2013

SOUTH SAN FRANCISCO, Calif., Sept. 5, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura (ITP) pending discussions with regulatory agencies. Rigel believes that a Phase 3 clinical program would encompass approximately 150 patients and can be completed in 2015. Rigel's other two lead programs, R333, a topical dermatological JAK/SYK inhibitor for discoid lupus erythematosus, and R348, a topical ophthalmic JAK/SYK inhibitor for dry eye, are presently in Phase 2 studies, with results expected in Q4 2013 and Q2 2014, respectively.  Rigel expects to advance one of these two molecules into a Phase 3 clinical program by 2014/15. The Company will not continue further development of fostamatinib for the treatment of rheumatoid arthritis or lymphoma due to insufficient efficacy findings from recent clinical trials and the competitive landscape for the agent in those indications.

"Strategically, we have made a decision to concentrate our resources on the programs that we believe hold the greatest potential for a near term path to market," said James M. Gower, chairman and chief executive officer of Rigel.  "The size and scope of these clinical programs are such that we can fund and manage them in-house, thereby maintaining control and flexibility over their development." 

As a consequence of prioritizing projects and looking to conserve the Company's cash resources, Rigel also announced that it has reduced its workforce by 18%, resulting in the elimination of 30 positions, mostly from the drug discovery area.  The Company is still assessing the restr
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Rigel Announces First Quarter 2012 Financial Results
2. Rigel Advances Asthma Programs: Two Inhaled Drug Candidates Take Aim at Acute and Chronic Lung Disease
3. Rigel Announces Second Quarter 2012 Financial Results
4. Rigel Initiates Phase 2 Clinical Studies with R343 for Asthma and R333 for Discoid Lupus
5. Rigel to Present at UBS Global Life Sciences Conference
6. Rigel Announces Third Quarter 2012 Financial Results
7. Rigel to Present at Jefferies 2012 Global Healthcare Conference in London
8. Rigel to Present at BIO CEO & Investor Conference
9. Rigel Announces Participation at Two Investor Conferences
10. Rigel Announces Fourth Quarter and Year End 2012 Financial Results
11. Rigel Announces First Quarter 2013 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Nov. 7, 2011 Inovio Pharmaceuticals, Inc. (NYSE AMEX: ... 30, 2011. Total revenue was $2.6 million and $8.2 ... compared to $1.3 million and $3.8 million for the same periods ... nine months ended September 30, 2011, were $9.0 million and $24.0 ...
... CHICAGO, Nov. 7, 2011 UCB today announced findings ... rates to Cimzia ® (certolizumab pegol) plus methotrexate ... effect on structural joint damage in patients with moderate ... responses were found by both RAPID3 (Routine Assessment of ...
Cached Medicine Technology:Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 2Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 3Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 4Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 5Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 6Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 7Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 8Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results 9New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 2New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 3New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 4New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 5New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 6New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 7New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 8New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 9New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 10New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 11New RAPID 1 Post-Hoc Analysis Showed Early Response to Cimzia® (certolizumab pegol) at Week 12 was Predictive of Week 52 Response 12
(Date:4/24/2014)... On April 28, the Center for BrainHealth will ... our most pressing brain-related challenges at its inaugural ... Resilience and Regeneration." Featured speakers will include Dr. ... the Center for BrainHealth, U.S. Senator Chuck Grassley ... Doggett, Deputy Assistant Secretary for Policy and Early ...
(Date:4/24/2014)... Depression affects more than one out of three ... study released in The Lancet Respiratory Medicine ... symptoms physically rather than mentally. , It is ... mental health and functional outcomes of critical care ... assistant professor of Medicine, and it highlights a ...
(Date:4/24/2014)... LA The National Science Foundation has awarded ... Experiences for Undergraduates (REU) Site grant in the ... training of undergraduates from diverse social and educational ... New Orleans area. The project will provide ... summers of 2014-16. It will be led ...
(Date:4/23/2014)... immigrants from Sub-Saharan Africa, Latin America and Caribbean ... to new research from St. Michael,s Hospital. , ... Journal of Obstetrics and Gynaecology , assessed the ... and native-born women in six high-immigration countries ... and Valencia) and the United States (California, New ...
(Date:4/23/2014)... 23, 2014 The American Society for Radiation Oncology ... of Postoperative Radiation Therapy for Endometrial Cancer: An ... adjuvant radiation therapy in the treatment of endometrial ... the May-June 2014 issue of Practical Radiation ... of ASTRO. The full-length guideline is available as ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 2Health News:Vanderbilt study finds physical signs of depression common among ICU survivors 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... use a new combination of the chemotherapy, Capecitabine, together ... have an 88 percent chance of surviving the cancer ... at the plenary session, October 3, 2011, at the ... Oncology (ASTRO). "The results of the trial allow ...
... released this week, challenges people to test their knowledge ... they learn about the complexities of the disease, which ... Californians. Developed as a free download by the ... and QuantiaMD, a company headquartered in Waltham, Massachusetts, the ...
... The University of North Carolina at Chapel Hill has ... Institute of Diabetes and Digestive and Kidney Diseases to ... Reduce Health Disparities (CDTR). Its mission is to reduce ... resources and support to foster translational research in North ...
... from Rhode Island Hospital researchers suggests that controlling cholesterol may ... non-steroidal anti-inflammatory drugs (NSAIDs) such as naproxen. The findings are ... in clinically relevant animal models when high cholesterol is a ... the journal Surgery . NSAIDs are among ...
... health challenges earlier than their fellow seniors, researchers ... lives of 8,700 older people, a Case Western ... reported physical limitations by African American women in ... finding surfaced as researchers looked generally at how ...
... the Witwatersrand goldfields, not far from bustling Johannesburg, South Africa, ... littered with mounds of waste and underlain by a deep ... with water. Today, the mines are producing less and less ... estimate the volume of acid mine drainage from abandoned mines ...
Cached Medicine News:Health News:Chemo plus radiation before surgery increases tumor response for rectal cancer 2Health News:Interactive mobile app from UCSF and QuantiaMD teaches people how to manage diabetes 2Health News:Interactive mobile app from UCSF and QuantiaMD teaches people how to manage diabetes 3Health News:New UNC Center for Diabetes seeks to reduce health disparities 2Health News:New UNC Center for Diabetes seeks to reduce health disparities 3Health News:Rhode Island Hospital researchers find possible cardiovascular risk with NSAID use 2Health News:African-American women develop functional challenges earlier than others 2Health News:African-American women develop functional challenges earlier than others 3
Inquire...
... a premium agarose used for isolating DNA ... produces clear sharp bands, with no smearing ... UltraClean Forensic Agarose is tested and certified ... activity and DNA contamination. Meets ...
... 1000 is specifically formulated for high resolution ... <1000 bp. This standard melting temperature agarose ... as 10 bp difference in size. ... gel structure for better handling and improved ...
Excellent multi purpose agarose Nuclease-free, Gel point (1.5%): 36 1.5 C, EEO: 0.05-0.13 Gel strength (1%): > 1200 g/cm 2 ....
Medicine Products: